TRexBio
PrivateLast Round
Series B
Extension
Jan 27, 2026
Total Funding Raised
$219M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
TRexBio is a biotechnology company that develops immunoregulatory medicines by mapping human tissue regulatory T cell behavior to disease processes to identify novel therapeutic targets.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TRexBio Comparables
Compare TRexBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mozart Therapeutics | 84% | |
| Sonoma Biotherapeutics | 80% | |
| Egle Therapeutics | 80% |
TRexBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 27, 2026 | ||||
| Series B | Nov 13, 2024 | ||||
| Series A Extension | Mar 8, 2022 | ||||
| Series A | Jun 22, 2021 |
Key People
Founding team and executive leadership
TRexBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Avego Management | Series B, Series B Extension |
| Janus Henderson Group | Series B Extension |
| Agent Capital | Series B |
| Balyasny Asset Management L.P. | Series B Extension |
| SV Health Investors | Series B, Series A, Series A Extension, Series B Extension, Seed |
| Alexandria Venture Investments | Series B, Series A, Series A Extension, Series B Extension |
| Pfizer Ventures | Series B, Series A, Series A Extension, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 79% MoM, from 4.9K to 8.9K.
- Jul 29, 2026
Monthly visitors grew 66% MoM.
Recent news
Latest coverage and updates
- goes_publicSep 18, 2026
TRex Bio, Inc. was planning to go public on Sep 18th '26.
TRexBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TRexBio's valuation, stock price, and market status.
Is TRexBio a public or private company?
TRexBio is a private company.
What is the current stock price of TRexBio?
TRexBio is a private company with no public stock price. No recent secondary market data is available.
How much is TRexBio worth (valuation)?
Valuation information for TRexBio is not publicly available.
Can I buy TRexBio stock?
TRexBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was TRexBio's last funding round?
TRexBio's most recent funding round was Series B Extension on January 27, 2026.
Who are the main investors in TRexBio?
Key investors in TRexBio include Janus Henderson Group, Balyasny Asset Management L.P., SV Health Investors, Delos Capital Partners, Polaris Partners.
Will TRexBio IPO soon?
No public IPO plans have been announced for TRexBio.
How can I track TRexBio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TRexBio's secondary market activity and sign up for updates.